Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (463)	2/24/2005 10:40:05 PM
From: Biomaven	Read Replies (1) \| Respond to of 946

I've never seen this study with the 75% excretion unchanged in the urine. Certainly it was not mentioned in the recent comprehensive discussion that Zeta posted. If you look at that paper (I have the full text with diagrams thanks to Zeta) it is clear the drug stays in the body for a very long time - up to three weeks after a single dose. It very slowly gets converted to the active form - plasma levels of the active form mirror those of the parent drug, but at a much lower level. But the real key is to what extent the parent drug is getting sequestrated in tumors and converting to active form there. Really you'd have to do some sort of radioactive tracer version of the drug to study that, and it doesn't look to me like it's been done yet. Peter